Study Evaluating Pantoprazole in Children With GERD

  • Tell a FriendPrint

The purpose of this study is to characterize the PK profile, safety and tolerability of single and multiple doses of pantoprazole in children aged 1 through 11 years with endoscopically proven GERD...

Brief Summary

Official Title: “A Multicenter, Randomized, Open Label, Single, and Multiple Dose Study of the Safety and Pharmacokinetics of 2 Dose Levels of Pantoprazole Sodium in Children Aged 1 Through 11 Years With Endoscopically Proven GERD”

The purpose of this study is to characterize the PK profile, safety and tolerability of single and multiple doses of pantoprazole in children aged 1 through 11 years with endoscopically proven GERD.

  • Study Type: Interventional
  • Study Design: Allocation: Randomized, Endpoint Classification: Pharmacokinetics Study, Intervention Model: Single Group Assignment, Masking: Open Label, Primary Purpose: Treatment
  • Study Primary Completion Date: November 2007

Intervention(s) in this Clinical Trial

  • Drug: pantoprazole for approximately 9 weeks.

Outcome Measures for this Clinical Trial

Primary Measures

  • Maximum Observed Plasma Concentration (Cmax)
    • Time Frame: Predose (0 hour), and 0.5, 1, 2, 4, 6, 12 hours postdose
      Safety Issue?: No
  • Time to Reach Maximum Observed Plasma Concentration (Tmax)
    • Time Frame: Predose (0 hour), and 0.5, 1, 2, 4, 6, 12 hours postdose
      Safety Issue?: No
  • Area Under the Curve From Time Zero to Last Quantifiable Concentration [AUC (0-t)]
    • Time Frame: Predose (0 hour), and 0.5, 1, 2, 4, 6, 12 hours postdose
      Safety Issue?: No
  • Area Under the Curve From Time Zero to Extrapolated Infinite Time [AUC (0 - ∞)]
    • Time Frame: Predose (0 hour), and 0.5, 1, 2, 4, 6, 12 hours postdose
      Safety Issue?: No
  • Plasma Decay Half-Life (t1/2)
    • Time Frame: Predose (0 hour), and 0.5, 1, 2, 4, 6, 12 hours postdose
      Safety Issue?: No
  • Apparent Oral Clearance (CL/F)
    • Time Frame: Predose (0 hour), and 0.5, 1, 2, 4, 6, 12 hours postdose
      Safety Issue?: No
  • Terminal-Phase Volume of Distribution (Vz/F)
    • Time Frame: Predose (0 hour), and 0.5, 1, 2, 4, 6, 12 hours postdose
      Safety Issue?: No
  • Plasma Concentrations After Multiple Doses
    • Time Frame: Hours 2 and 4 on Day 7
      Safety Issue?: No

Criteria for Participation in this Clinical Trial

Inclusion Criteria:

  • Endoscopically proven GERD diagnosed within 6 months before study entry.
  • Weight must be equal to or over 8.3 kg; for subjects 6 years or greater, weight must be equal to or under 25 kg

Exclusion Criteria:

  • History of GI disorders, ie, unrepaired tracheal esophageal fistula, GI malabsorption, Eosinophilic esophagitis
  • Subjects 6-11 years old unable to swallow tablets

Gender Eligibility for this Clinical Trial: Both

Minimum Age for this Clinical Trial: 1 Year

Maximum Age for this Clinical Trial: 11 Years

Are Healthy Volunteers Accepted for this Clinical Trial?: No

Clinical Trial Investigator Information

Lead Investigator: Wyeth is now a wholly owned subsidiary of Pfizer Industry

Overall Clinical Trial Officials and Contacts

Medical Monitor Study Director Wyeth is now a wholly owned subsidiary of Pfizer  

Additional Information

Information obtained from ClinicalTrials.gov on February 12, 2012

Link to the current ClinicalTrials.gov record. http://clinicaltrials.gov/show/NCT00141817

Study ID Number: 3001B3-334

ClinicalTrials.gov Identifier: NCT00141817

Health Authority: United States: Food and Drug Administration

  • Tell a FriendPrint

Clinical Trials content is provided directly by the U.S. National Institutes of Health via ClinicalTrials.gov and is not reviewed separately by ClinicalTrialsFeeds.org. Every page of specific clinical trials information contains a unique identifier which can be used to find further details directly from the National Institutes of Health.

The URL of this page is:
http://clinicaltrialsfeeds.org/clinical-trials/show/NCT00141817